Skip to main content
Clinical Trials/ACTRN12605000235606
ACTRN12605000235606
Active, not recruiting
未知

Determinants of vascualr dysfunction in chronic kidney disease

Pfizer0 sites105 target enrollmentAugust 26, 2005

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Pfizer
Enrollment
105
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 26, 2005
End Date
TBD
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Pfizer

Eligibility Criteria

Inclusion Criteria

  • All patients on haemodialysis or peritoneal dialysis for Chronic kidney disease, including patients with diabetes; Patients should be stable on dialysis for at least 6 months with adequate indices of dialysis (Fractional Reduction of Urea, FRU \> 0\.67 or Kt/V \> 0\.3\); All patients with moderate\-to\-severe chronic kidney disease (GFR \< 40ml/min), including patients with diabetes.

Exclusion Criteria

  • Nephrotic\-range proteinuria; Active upper gastro\-intestinal dyspepsia; Muscular disorders; Liver and muscle enzymes \> 2 times upper limit of normal; Alcohol consumption \> 3 standard drinks/day; Use of antioxidant vitamin supplements other than multivitamin B/folic acid preparations routinely used in haemodialysis patients; Immunosuppressive therapy for renal transplantation; Cardiovascular event or unstable cardiovascular disease in preceding 6 months; Drugs known to affect lipid\-metabolism (eg. fish oil supplements); Significant psychiatric disorder; Active infection.

Outcomes

Primary Outcomes

Not specified

Similar Trials